Wechselwirkungen · Duaklir Genuair
Duaklir Genuair 340 micrograms /12 micrograms inhalation powder · Abschnitt 4.5 · PDF-Seite 4
HOS-131021 · Präparat HOS-096989
Duaklir Genuair should be administered with caution to patients being treated with medicinal products known to prolong the QTc interval such as monoamine oxidase inhibitors, tricyclic antidepressants, antihistamines or macrolides because the action of formoterol, a component of Duaklir Genuair, on the cardiovascular system may be potentiated by these medicinal products. Medicinal products that are known to prolong the QTc interval are associated with an increased risk of ventricular arrhythmias.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T17:43:00Z · SHA-256 738d2adbd3dbff6f1351d068e555e9581680fef31b44535569ea13bcee8ad9c8 · Passage b9f60dc4b88d71a6ce3beb869ff10dfdd334652985ad2db1189012ffd248d1ab · Zeichen 1107–1607 im Abschnitt